ArticleScientific reports2022
Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Systematic effects of patient factors and scanner/protocol factors on a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Survival outcomes in prostate cancer patients treated at an Indian tertiary care centre.BJUI compass · 2026Article
- A Case-Control Study of Association Between Serum Levels of 19 Trace Elements with Prostate Cancer in Southwest China.Biological trace element research · 2025Article
- Multivariate Statistical Evaluation of 20 Metals/Metalloid Levels in the Serum of Patients with Prostate Gland Diseases.Indian journal of clinical biochemistry : IJCB · 2025Article
- Association between the use of proton pump inhibitors and serum PSA levels in the general U.S. population.World journal of urology · 2025Article
- Patient-specific prostate tumour growth simulation: a first step towards the digital twin.Frontiers in physiology · 2024Article
- Biomolecule-functionalized nanoformulations for prostate cancer theranostics.Journal of advanced research · 2023Review
- Review
- Zinc in Prostate Health and Disease: A Mini Review.Biomedicines · 2022Review
- Prostate-Specific Antigen Monitoring Using Nano Zinc(II) Metal-Organic Framework-Based Optical Biosensor.Biosensors · 2022Article
- Environmental Exposure to Metals, Parameters of Oxidative Stress in Blood and Prostate Cancer: Results from Two Cohorts.Antioxidants (Basel, Switzerland) · 2022Article
- The most effective but largely ignored target for prostate cancer early detection and intervention.Journal of Cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 3 countries.
Funding
Abstract
It is being debated whether prostate-specific antigen (PSA)-based screening effectively reduces prostate cancer mortality. Some of the uncertainty could be related to deficiencies in the age-based PSA cut-off thresholds used in screening. Current study considered 2779 men with prostate cancer and 1606 men without a cancer diagnosis, recruited for various studies in New Zealand, US, and Taiwan. Association of PSA with demographic, lifestyle, clinical characteristics (for cases), and the aldo-keto reductase 1C3 (AKR1C3) rs12529 genetic polymorphisms were analysed using multiple linear regression and univariate modelling. Pooled multivariable analysis of cases showed that PSA was significantly associated with demographic, lifestyle, and clinical data with an interaction between ethnicity and age further modifying the association. Pooled multivariable analysis of controls data also showed that demographic and lifestyle are significantly associated with PSA level. Independent case and control analyses indicated that factors associated with PSA were specific for each cohort. Univariate analyses showed a significant age and PSA correlation among all cases and controls except for the US-European cases while genetic stratification in cases showed variability of correlation. Data suggests that unique PSA cut-off thresholds factorized with demographics, lifestyle and genetics may be more appropriate for prostate cancer screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.